Latest news
Jazz Pharmaceuticals: Buy Rating Reiterated as Actio Bioscience Acquisition and ABS-1230 Growth Potential Support Unchanged $307 Price Target - TipRanksTipRanks · Mon, 10 Aug 2026 17:29:04 GMTJazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Mon, 10 Aug 2026 16:17:36 GMTJazz expands epilepsy portfolio with buy of Actio Biosciences - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 15:16:17 GMTJazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - ReutersReuters · Mon, 10 Aug 2026 15:11:12 GMTJazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline - BioSpaceBioSpace · Mon, 10 Aug 2026 14:48:45 GMTJazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 14:40:00 GMTJazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 14:22:59 GMTJazz to buy Actio for up to $1.32B, gaining epilepsy asset - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 13:48:18 GMT